Join Now

Patient 4821 · Longitudinal record

CONSENTED

2019

2021

2023

2025

Today

Clinical

Imaging

Pharmacy

Claims

ePRO

Transform the way you generate
real-world evidence.

Move beyond one-time data pulls with durable, patient-authorized connections that deliver complete records and patient-reported outcomes, continuously and at scale.

Request a demo

Stop buying snapshots.
Start building connections.

Traditional Model

AllClear

Data scope

Fragments, de-identified only

The complete record: clinical, images, claims, insurance, pharmacy, ePRO

Freshness

Static, one-time snapshot

Live, updated on demand

Basis for access

Institutional B2B exchange

Patient-authorized connection

Reusability

Single use per request

Reusable across studies

Traditional Model

AllClear

Data scope

Fragments, de-identified only

The complete record: clinical, images, claims, insurance, pharmacy, ePRO

Freshness

Static, one-time snapshot

Live, updated on demand

Basis for access

Institutional B2B exchange

Patient-authorized connection

Reusability

Single use per request

Reusable across studies

Data scope

Traditional Model

Fragments, de-identified only

AllClear

The complete record: clinical, images, claims, insurance, pharmacy, ePRO

Freshness

Traditional Model

Static, one-time snapshot

AllClear

Live, updated on demand

Basis for access

Traditional Model

Institutional B2B exchange

AllClear

Patient-authorized connection

Reusability

Traditional Model

Single use per request

AllClear

Reusable across studies

An alternative to tokenization: instead of matching records with anonymous codes, AllClear links every source to one verified patient who has given consent.

The whole patient, for as long as the study needs.

AllClear Research
PatientsDataFollow-upNetwork
Dr. Lena OrtizLO
ONC-214 · Lung cancer outcomes
Patient connections
1,248
connected patients
PatientProvidersConnected sinceLast update
P-0412
64 · F
M
H
B
+2
Mar 2024
2h
P-1180
57 · M
B
D
Apr 2024
Yesterday
P-0077
71 · F
M
N
H
+1
Jan 2024
3d
P-2306
49 · M
L
M
Jun 2024
1w
P-0931
68 · F
H
B
M
+3
Feb 2024
2w

Not a better dataset. A different kind of evidence.

1:1

Patient connections, reusable across studies

100%

Record retrieval success rate*

01 - See the whole patient, not a fragment

One verified record across providers, labs, pharmacies, and payers.

02 - Run the studies de-identified data can’t

Re-contact, longitudinal follow-up, and linkage across sources.

03 - Skip the licensing marathon

Go from data request to analysis through a single gateway.

And it compounds. The same patient networks power faster trial matching, post-approval safety surveillance, and stronger patient support programs.

*AllClear does all the work to retrieve each patient’s records; however, the records must exist, there may be steps that only the patient can complete, and providers may apply legal exceptions or fees in certain cases.

Patient-authorized access transforms that data into a strategic asset. That is not a better data purchase. It is a new relationship with the patient.

JT

Jeff Trotter

Real-World Evidence Pioneer, Independent Consultant

Patient-authorized access transforms that data into a strategic asset. That is not a better data purchase. It is a new relationship with the patient.

JT

Jeff Trotter

Real-World Evidence Pioneer, Independent Consultant

Re-contact, longitudinal follow-up, and linkage across sources stop being special projects and become how you work. That is not a better dataset. It is a different kind of evidence.

DB

Diana Brixner

Professor Emeritus of Pharmacotherapy, The University of Utah

Re-contact, longitudinal follow-up, and linkage across sources stop being special projects and become how you work. That is not a better dataset. It is a different kind of evidence.

DB

Diana Brixner

Professor Emeritus of Pharmacotherapy, The University of Utah

See how AllClear powers real-world evidence for your next study.

See how AllClear powers real-world evidence for your next study.

See how AllClear powers real-world evidence for your next study.